DrMartina Wallace

I lead a research group based at the Conway Institute of Biomolecular and Biomedical Research. Our work focuses on understanding and modifying cellular metabolism to develop treatments for diseases associated with obesity and metabolic syndrome, such as MASLD and Type 2 diabetes. We specialize in stable isotope tracing of metabolites combined with mass spectrometry to illuminate changes in the metabolic network. These techniques are complemented by classic molecular biology approaches in vitro and by diet or pharmacological interventions in vivo to manipulate organismal metabolism.

Some recent and ongoing projects include:

1.     Targeting Hepatic Stellate Cell (HSC) Metabolism to Treat Liver Fibrosis
Metabolic dysfunction-associated steatohepatitis (MASH) is increasing in prevalence worldwide. The stage of fibrosis in MASH patients is a key predictor of mortality; however, treatment options remain limited. Hepatic stellate cell transdifferentiation is the primary source of myofibroblasts driving fibrosis, making it an attractive therapeutic target. As the metabolic requirements of myofibroblasts differ dramatically from those of quiescent HSCs, metabolic enzymes may represent viable intervention points. We are employing stable isotope tracers and metabolite analysis in vitro and in vivo to identify and test whether altering key metabolic nodes can modulate HSC transdifferentiation.

2.     The Impact of Food-Derived and Atypical De Novo Synthesized Lipids on Health
We have a strong interest in specific fatty acids such as mmBCFAs and polar lipids such as sphingolipids, and the impact of dietary sources of these fatty acids and lipids on health. Previously published papers related to this include PMID: 38277883, PMID: 30327559, PMID: 33399331.

3.     Targeting Branched-Chain Amino Acid (BCAA) Catabolism in Type 2 Diabetes
Altered BCAA catabolism is a well-established feature in Type 2 diabetes, contributing to elevated circulating BCAA levels. Enhancing BCAA breakdown has shown promise for improving glycaemic control in both preclinical models and clinical trials. We are investigating the mechanisms by which increased BCAA catabolism improves glucose homeostasis and examining additional metabolic benefits of targeting this pathway. Related publication: PMID: 39551140.

Potential applicants:
Please contact me if you are interested in applying for a PhD or postdoctoral fellowship.